Shares of the telehealth company Hims & Hers Health Inc. (HIMS) soared 5.07% in Wednesday's intraday trading session.
The stock surge is likely driven by the buzz and attention surrounding Hims & Hers' provocative Super Bowl commercial that criticized weight-loss drug makers and the U.S. healthcare system. While prompting backlash from Senators Richard Durbin and Roger Marshall, who have requested an FDA investigation into potential misleading claims, the controversial ad has generated significant publicity for the company.
Despite the controversy, Hims & Hers remains a highly rated stock in its industry group, with strong rankings for its Composite Rating, EPS Rating, and Relative Strength Rating according to IBD Stock Checkup. The company is set to report its earnings on February 24th, which could provide further insight into its performance and outlook.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.